Featured Articles
In an exciting step for scleroderma treatment, the USA’s Food and Drug Administration (FDA) have approved the use of nintedanib in treating interstitial lung disease associated with systemic sclerosis, making this the first therapy for those living with this condition caused by lung fibrosis.
Featured Articles
Many of our community will understand the difficulties that come with trying to secure disability benefits. As scleroderma is still a little known illness, it can take some hard work to secure the benefits you are entitled to. To help you figure out how to approach the process, we’ve asked members of our community to share their experiences.
Featured Articles
A recent review published in Nature Rheumatology focused on research into the classification of scleroderma, which suggests that the current classification does not capture the heterogeneity of the condition.
News By Type
Categories
Date
